Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 7/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL788177 | 0.90 | KDR (0.51) | MAPTKDRTRPV1CA9LMNA | |
| SCHEMBL15052255 | 0.89 | AKR1C3 (0.48) | AKR1C3AKR1C2MAPTKDRCSNK2A1 | |
| SCHEMBL15053523 | 0.88 | AKR1C3 (0.47) | AKR1C3AKR1C2MAPTKDRCSNK2A1 | |
| SCHEMBL787904 | 0.84 | KDR (0.57) | KDRCA9 | |
| SCHEMBL15052555 | 0.82 | KDR (0.58) | MAPTKDRCA9TAS2R14 | |
| SCHEMBL787702 | 0.80 | KDR (0.51) | MAPTKDRCA9 | |
| SCHEMBL787781 | 0.79 | KDR (0.53) | MAPTKDRTRPV1CA9 | |
| SCHEMBL15052536 | 0.78 | KDR (0.53) | MAPTKDRCSNK2A1CA9 | |
| SCHEMBL12475041 | 0.78 | KDR (0.58) | KDRCA9TAS2R14 | |
| SCHEMBL15052347 | 0.78 | KDR (0.58) | MAPTKDRCA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | AKR1C3 3184/4885AKR1C2 2422/4885MAPT 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.